Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cyteir Therapeutics (CYT) stocks in Canada

Learn how to easily invest in Cyteir Therapeutics stocks.

Cyteir Therapeutics is a biotechnology business based in the US. Cyteir Therapeutics stocks (CYT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.23 – a decrease of 19.42% over the previous week. Cyteir Therapeutics employs 22 staff and has a market cap (total outstanding stock value) of $216.5 million.

How to buy shares in Cyteir Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Cyteir Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cyteir Therapeutics stock price (NASDAQ:CYT)

Use our graph to track the performance of CYT stocks over time.

Cyteir Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$5.81
52-week range$5.76 - $23.10
50-day moving average $12.66
200-day moving average $16.48
Wall St. target price$31.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.20

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Cyteir Therapeutics price performance over time

Historical closes compared with the close of $5.81 from 2022-01-18

1 week (2022-01-12) -19.42%
1 month (2021-12-17) -41.31%
3 months (2021-10-19) -67.47%
6 months (2021-07-19) -66.16%
1 year (2021-01-15) N/A
2 years (2020-01-15) N/A
3 years (2019-01-15) N/A
5 years (2017-01-15) N/A

Cyteir Therapeutics financials

Gross profit TTM $-16,591,000
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value $5.64
Market capitalisation $216.5 million

TTM: trailing 12 months

Cyteir Therapeutics share dividends

We're not expecting Cyteir Therapeutics to pay a dividend over the next 12 months.

Have Cyteir Therapeutics's shares ever split?

Cyteir Therapeutics's shares were split on a 2:1 basis on 18 September 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cyteir Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cyteir Therapeutics shares which in turn could have impacted Cyteir Therapeutics's share price.

Cyteir Therapeutics overview

Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts. .

Stocks similar to Cyteir Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site